June #135 : B Careful - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Jagged Little Pills

Happy Feet

Bunny Business




Playing the Percentages

Soul Survivors

B Careful

In the Running

Seeing Double

Write of Passage

Salad Daze

From Here to Paternity

Summer Share




Papa, Can You Hear Me?

Outside Chance

Send Us the Bill

Climb Every Mountain

Farewell Tour

Hot Dates-June 2007

Agent Provocateur

Mixed (Up) Media

Another AIDS Movie for Philadelphia

Say What?!-June 2007

Attention, K-Y Shoppers

The Next Best Thing to Being There

Getting Crafty

Baggage Claim




Editor's Letter-June 2007

Mailbox-June 2007

Catch of the Month—June 2007



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

June 2007


B Careful

by Laura Whitehorn

A Hepatitis B med may breed HIV drug resistance

Do you fit this description: You have both HIV and hepatitis B (HBV), don’t need to take HIV meds but do need treatment for hep B? If so, avoid the new HBV med Baraclude (entecavir)—at least for now. A recent study by researchers at Johns Hopkins School of Medicine in Baltimore showed that Baraclude suppresses HIV along with HBV.

That may sound good, but it means that taking Baraclude solo—without additional HIV meds—could allow your HIV to become resistant to the drug and other nukes. (HIV monotherapy can lead to drug resistance.) That, in turn, could limit your choices when you do begin HIV meds. Scientists originally thought Baraclude suppressed HBV but not HIV, setting it apart from some other HBV drugs (Hepsera and Epivir-HBV), which attack both viruses.

The new data prompted Bristol-Myers Squibb, maker of Baraclude, to alert HIV docs to the problem in February. But BMS’s Richard Colonno, PhD, says that more investigation is needed. In ten years of testing Baraclude, Colonno says, BMS never found evidence that it suppresses HIV. BMS and Hopkins researchers will team up to resolve the conflict.  


[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    usuallyhappy
    Palm Springs
    California


    sefarady
    Palm Springs
    California


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.